FDA Approves Generic Versions Of Breast Cancer Medication Letrozole

The Food and Drug Administration approved June 3 more than a dozen new generic versions of the breast cancer drug Femara (letrozole), a medication used as add-on treatment for the early stages of the disease.

Femara also is prescribed as a first- and second-line treatment for advanced breast cancer, FDA said in a notice. The drug is a branded product of Novartis.

As of June 3, the following companies’ generics of Femara have been approved by FDA: Mylan Inc., Natco Pharma Ltd., Indicus Pharma LLC, Synthon Pharmaceuticals Inc., Teva Pharmaceuticals USA, Fresenius Kabi Oncology Plc., Endo Pharmaceuticals Inc., Roxane Laboratories ...